Scleroderma is a chronic disorder manifested by excessive synthesis and deposition of collagen in skin and connective tissue, vascular abnormalities, and autoimmunity. Using microarray and real-time PCR data, we show that intradermally expressed interferon g (IFN-g), generated after intradermal injection of IFN-g-coding plasmid, and non-invasive topical nanoparticle (TNP) treatment with IFN-g-coding plasmid, decreased collagen synthesis (via the Jak/Stat 1 pathway), upregulated Th1 cytokine levels, and downregulated the profibrotic cytokine Transforming growth factor b and the Smad pathways in the Tsk/ þ (tight-skin scleroderma) mouse model. The TNP gene delivery system was constructed from gemini surfactant 16-3-16 and IFN-g-coding plasmid. Topical administration of IFN-g-coding plasmid in TNPs was effective in expressing IFN-g levels after a 20-day treatment regimen without increased TLR4, CCL2, CCL11 and CCR2 mRNA levels that were observed in injected animals, signs considered to be innate responses to injury. The more uniform transgene IFN-g expression caused significant (70 --72%) collagen reduction, as assessed by reverse transcription real-time PCR. These results demonstrate efficient in vivo transfection using a gemini surfactant-based TNP delivery system able to modulate excessive collagen synthesis in scleroderma-affected skin.
INTRODUCTION
Scleroderma is a chronic disorder manifested by excessive synthesis and deposition of collagen (both type I and type III) in skin and connective tissue, vascular abnormalities, and autoimmunity. In morphea, a localized form of scleroderma, the lesions are confined to the skin and occur as plaques (morphea en plaque) or indurated papular lesions (guttate morphea). As the condition evolves, more extensive lesions appear and subcutaneous tissue is replaced by dense collagenous tissue, a process that can progress to involve muscle and fascia. 1 Sclerotic fibroblasts (myofibroblasts) are capable of multiple in vitro passages, thus their accumulation might be responsible for the fibrosis characteristic of the disorder. 2 These fibroblasts produce excessive collagen even without an immune stimulus, suggesting the dysfunction of some regulatory genes associated with phenotypic selection (that is, the subpopulation of fibroblasts producing excessive collagen being amplified at the expense of normal fibroblasts). The stimulus for excessive collagen production originates from immune mechanisms. The development of sclerosis consists of three major steps: (1) cellular infiltration and vascular damage due to external stimuli or genetic factors, (2) inflammation due to the activation of monocytes and T-cells and (3) fibrosis ( Figure 1 ). 3 Recently, it has been demonstrated that genetic polymorphism in several genes such as T-box expressed in T cells (TBX21), signal transducers and activators of transcription 4 (STAT4), IFN regulatory factor 5 (IRF5) B-cell scaffold protein with ankryn repeats (BANK1) and tumor necrosis factor superfamily-4 (TNFSF4) are factors in the susceptibility to scleroderma. 4 Clinicians face significant challenges in the treatment of scleroderma because of its various clinical manifestations, the presence of autoimmune components and the diversity of laboratory features. Transforming growth factor b (TGF-b), interferon g (IFN-g), interleukin 4 (IL4), endothelin and connective tissue growth factor are some of the pharmacological candidates for intervention. 5 Animal studies indicated that administration of IL-12-coding plasmid significantly reduced skin thickness and production of IL-4, and increased IFN-g levels. 6 The same effect could be achieved by blocking the endogenous TGF-b signaling with anti-TGF-b antibodies or TGFB1 antisense oligonucleotide. 7 Zhou et al. 8 analyzed fibroblasts from scleroderma patients and found increased SPARC (secreted protein, acidic and rich in cysteine) levels. This protein regulates the assembly and deposition of extracellular matrix components, and its modulation might contribute to control of the condition. The therapeutic applications of IFN-g derive from the many biological functions of this cytokine. Its effect on collagen synthesis was exploited when treating scleroderma; 9 however, when IFN-g was injected directly into the skin, it activated TNF-a and upregulated the expression of ICAM1 and VCAM1. This lead to inflammation and adhesion of leukocytes to the blood vessels, causing flu-like symptoms and more severe adverse effects such as digital infarction and renal failure in systemic scleroderma patients. 9 Although IFN-g activates genes similar to type I interferons, which can trigger autoimmune diseases such as systemic and cutaneous lupus erythematosus, Sjogren's syndrome, systemic sclerosis and autoimmune hepatitis, no exacerbation of autoimmune diseases have been reported in humans. This might be due to the limited clinical applications. 10 Generating IFN-g in situ using gene delivery vectors, however, could greatly increase the half-life of this protein drug while reducing its systemic side effects.
IFN-g directly suppresses collagen synthesis in two ways ( Figure 2 ): indirectly through Janus kinase (Jak)/ signal transducer and activator of transcription 1 (Stat1) signaling, and directly through the Y-box-binding protein (YB1) pathway. IFN-g blocks COL1A2 promoter activity by Jak/Stat1a activation. The activated Stat1-a competes with the TGF-b-activated Smad2/3 (ref.11) or the limited amount of the cellular cofactor p300/CBP, blocking transcription of COL1A2. 12 The second pathway involves activation of YB1, which directly interacts with the promoter region of COL1A2, blocking its transcription. Additionally, YB1 binds mRNA in the cytoplasm, which could constitute yet another way to block collagen synthesis at the translational level. 13 IFN-g also directly stimulates prostaglandin production, a fibroblast growth inhibitor in monocytes.
Various animal models are available to study the cutaneous modifications in scleroderma.
14 The Tsk1 mouse is particularly relevant because of its increased collagen synthesis in the skin and accumulation in the dermis. The morphological changes are caused by a spontaneous mutation of the fibrillin-1 gene (FBN1) on chromosome 2. Homozygous Tsk/Tsk embryos die in utero, but the heterozygous Tsk/ þ (Fbn1 Tsk þ / þ Pldn pa genotype) animals are viable and present the pathological changes in the skin characteristic of scleroderma. 15 Littermates (pa/pa) of þ Pldn pa / þ Pldn pa genotype do not show signs of the disease. We have previously shown that gemini surfactant-based selfassembled DNA nanoparticles (topical nanoparticles (TNPs)) deliver IFN-g-coding plasmid into keratinocytes in vitro and into skin of normal (CD1) mice, 16 as well as in IFN-g-deficient knockout mice. 17 The level of IFN-g gene expression in vivo was similar in the two animal models and was indicative of pharmacologically relevant levels. In this paper, our objective was to evaluate the delivery of plasmid DNA coding for IFN-g via intradermal injection and topical treatment (at a topical dose of 100 mg) with plasmid DNA coding for IFN-g encapsulated in gemini nanoparticles in Tsk/ þ mice. Several aspects of the treatment, such as changes in cytokine profile, adhesion molecules and autoimmune disease marker gene expression, and the effect of the expressed IFN-g on collagen production in the skin, were evaluated using microarray analysis.
RESULTS AND DISCUSSION
Characterization of expression of localized cutaneous scleroderma-related gene panel in Tsk/ þ mice The baseline expression of a panel of selected genes relevant in the pathogenesis of cutaneous scleroderma was first evaluated in the Tsk/ þ mouse strain. We compared differential expression of a pre-selected group of 110 genes between Tsk/ þ animals and their non-affected littermates (pa/pa mice) in five categories, judged relevant, including (1) Th1/Th2/Th3 cytokines, (2) markers of autoimmune diseases and inflammatory response genes, After normalization and filtering the data for unreliable spots, a comparison between Tsk/ þ and pa/pa was performed (Figure 3 ). In total, expression of 17 genes was found to be different between the two genotypes of animals. Table 1 lists these genes along with their measured expression fold change differences between diseased and normal animals. As expected, procollagen Ia1 mRNA (Col1a1) levels in the Tsk/ þ animals were higher than in normal littermates. MMP3 and ADAMTS2, genes involved in extracellular matrix processing, were expressed at a lower level in the Tsk/ þ animals, compared with the non-diseased animals. Adamts2 has a role in the correct assembly of collagen fibers, and mutation of the ADAMTS2 gene causes changes in the tensile properties of the skin. 18 Adiponectin was also expressed at a lower level in Tsk/ þ mice. Adiponectin is produced in the adipocytes and its role and regulation are still controversial; in obese animals, low levels correlate with the presence of pro-inflammatory cytokines, Figure 3 . Microarray heat map of Tsk/ þ (red) and pa/pa (yellow) mice (n ¼ 4 for Tsk/ þ and n ¼ 2 for pa/pa mice). Differential expression of a pre-selected group of 110 genes in five categories: Th1/Th2/Th3 cytokines, markers of autoimmune diseases and inflammatory response genes, extracellular matrix/cell adhesion molecules, Stat/Smad signaling pathway molecules and cell surface markers. Bolded values indicate upregulation in the Tsk/+ animals.
Topical gene therapy for cutaneous scleroderma I Badea et al and in chronic inflammatory and autoimmune diseases, high levels of adiponectin are detected. 19 Lipomembraneous fat necrosis sometimes is associated with inflammatory and sclerotic conditions, 20 which ultimately might explain low adiponectin levels in the Tsk/ þ model. As the Tsk/ þ model is a genetic model, there were no significant differences regarding the immune response markers and cytokines, nor signs of an autoimmune disease between the tight-skin animals and their healthy littermates. Interestingly, CD2 and CD86 levels were significantly lower in the Tsk/ þ animals than in pa/pa littermates, whereas CD44 displayed the opposite behavior.
The Tsk/ þ mouse was originally proposed as a possible model for scleroderma because of duplication of the FBN1 gene, 21 which results in hyperplasia of the subcutaneous connective tissue, 22 increased collagen deposition leading to thickened dermis 23 --25 and tissue fibrosis. 26 Our results also indicate a significant increase of Col1a1 mRNA in the Tsk/ þ mice. Moreover, the increase of connective tissue growth factor and Smad2 mRNA (Table 1) , both having roles in increased collagen synthesis and deposition, support the choice of this animal model for evaluation of the effect of gene therapy on collagen deposition.
Quantitative evaluation of IFN-c gene expression by ELISA in skin homogenates of Tsk/ þ mice after treatment with TNPs IFN-g-coding plasmid was administered either by intradermal injection of the plasmid solution or topically on the skin using the gemini nanoparticle formulation. The 4-week (5 times per week) treatment consisted either of topical treatment with TNPs once a day (plasmid dose 100 mg cm À2 site; no treatment on weekends) or two intradermal injections weekly for 4 weeks (plasmid dose 2.5 mg per site).
Both TNP and intradermal treatments increased IFN-g expression in the skin of Tsk/ þ mice ( Figure 4 ). In our preliminary study, 3-day TNP treatment produced similar IFN-g levels to those measured in the skin of CD1 animals treated topically for 3 days with the TNP formulation, 16 as well as by topical treatment of IFN-g-deficient mice 17 (results not shown). In the Tsk/ þ mice, after the 20-day treatment regimen, intradermal injections with plasmid solutions appeared to produce higher transgene expression (1069 ± 612 pg cm
À2
), compared with topical application of TNPs (345 ± 275 pg cm À2 ) (Po0.1). No IFN-g was detected in the serum of any treatment groups.
In addition to IFN-g expression, green fluorescent protein (GFP) level was also monitored by confocal microscopy in the TNP-treated Tsk/ þ mice (Figures 5a --d) , intradermally injected Tsk/ þ animals (Figures 5e and f) and non-treated Tsk/ þ animals ( Figures 5g and h ). In the intradermally injected animals, the fluorescence was strong around the injection site but was confined to a smaller area. In the skin of animals treated topically, the fluorescence was weaker but distributed across the entire examined area. No GFP fluorescence was detected in the skin of control animals.
Early clinical studies indicated a significant decrease in skin thickness score and area score in systemic sclerosis-affected patients after intramuscular IFN-g administration (100 --500 mg m À2 three times weekly for 18 weeks). 27 More recent studies of intramuscular IFN-g injection indicated mixed results, 28 and side effects were common, mainly flu-like symptoms. 29 These poor clinical results might be attributed to the low levels of IFN-g in the tissues affected by sclerosis because of its short half-life of only 1.1 min; 30 the presence of side effects might be associated with systemic administration of this protein-based treatment. Injection of 100 mg IFN-g subcutaneously in the periphery of localized lesions did not produce the desired effect of reducing the size or extent of fibrosis in existing lesions, but was able to prevent the appearance of new lesions. The reason might be that IFN-g inhibits the synthesis of collagen, but has no effect on collagen-degrading enzymes. 31 The invasive administration of this therapeutic protein and the tissue damage caused might also have triggered an unwanted cytokine cascade. Treatment of scleroderma with in situ generated IFN-g could have several advantages compared with other treatment options. IFN-g neutralizes the effect of both IL-4 and TGF-b on fibroblasts and inhibits transcription of both COL1A2 and TGFB in the target cells. Anti-IL-4 or anti-TGF-b would abolish only the profibrotic effect of a single agent. A disadvantage of blocking TGF-b is that it can affect not only the hypertrophied skin but also other tissues such as vascular walls, cartilage and ligaments. The same disadvantage is seen in systemic halofuginone treatment, which reduces the collagen-producing cells. 32 In fibrotic disorders, the number of fibroblasts decreases with the progression of the disorder and many of them differentiate into myofibroblasts, which are characterized by excessive extracellular matrix synthesis, synthesis of tissue inhibitor of metalloproteinase (inhibits collagen degradation), increased reactivity to TGF-b and decreased sensitivity to IFN-g. 33, 34 Because of its effect on fibroblast proliferation, IFN-g could expand the number of healthy fibroblasts and restore the normal collagen homeostasis in the dermis. IFN-g can also have a role in restoring the immune balance by stimulation of Th1 cells.
Overall, IFN-g expression was at high levels in the skin of Tsk/ þ mice after the 4-week treatment with TNPs. Topical application led to protein levels similar to that achieved by intradermal injection, thus the topical non-invasive delivery route via gemini nanoparticles could be a feasible alternative. As a local therapeutic target for scleroderma, the keratinocytes in the epidermis could be triggered to express IFN-g transiently from plasmid DNA. By establishing an appropriate treatment regimen, therapeutic protein levels could be reached directly in the skin and the length of therapy could be decided based on the clinical appearance of the lesions (remission of the plaques), reduction of skin thickness score and increase of the elasticity of the skin. By developing an effective topical non-invasive dosage form for IFNg-coding plasmid and providing a sustained supply of IFN-g within the skin, a more effective approach to manage the cutaneous manifestations of scleroderma could be achieved.
Evaluation of gene expression in Tsk/ þ mice after topical treatment or intradermal injection Gene expression was measured in the skin of Tsk/ þ mice after the 4-week treatment with TNPs or after intradermal injection IFNg-coding plasmid. Gene expression was monitored in five categories: (1) Th1/Th2/Th3 cytokines, (2) growth factors, (3) adhesion molecules, (4) cell surface markers and (5) Stat/Smad signaling. Data were normalized and filtered as described in Materials and methods, resulting in 54 spots regarded as reliable. Figure 6 represents an unsupervised two-way hierarchical clustering of these data. By comparing all three groups of Tsk/ þ mice (intradermally injected, topically treated and untreated mice), we observed that animals were separated clearly into distinct treatment clusters. T-tests between the intradermally injected and untreated mice resulted in 21 significantly differentially regulated genes (Pp0.05) (Table 2a) . Moderately decreased expression was observed only of Col 4a1 (Po0.1) in the injected Tsk/ þ mice compared with untreated Tsk/ þ mice, but contrary to expectations, Col 1a1 and Col 3a1 levels were slightly elevated (Table 2a) . When comparing gene expression in mice receiving TNPs with the pattern from untreated animals, 10 genes were found to be significantly differentially regulated (Pp0.05) (Table 2b ). Moderately decreased expression of Col 3a1 and 4a1 levels (Po0.1) were observed in TNP-treated Tsk/ þ mice relative to untreated Tsk/ þ mice, but no change was seen in Col 1a levels (P ¼ 0.483) (Table 2b ). Despite measurable IFN-g levels, mRNA in the microarray set was not conclusive. The lack of correlation between mRNA and protein levels might be due to the very short half-life of IFN-g. 35, 36 50 m Figure 5 . Confocal one-photon images of GFP expression in the skin of Tsk/ þ mice, treated topically with TNP formulation (DNA-TNP-t) (a --d), injected intradermally with DNA solution (DNA-s-i) (e, f ) and untreated (control) (g, h). The images were recorded 15 --30 mm deep into the skin. GFP fluorescence (green buffer) and autofluorescence (red buffer) images were merged. All images were recorded at the same magnification. Figure 6 . Microarray heat map of intradermally injected (blue), topically treated (red) and untreated (yellow) Tsk/ þ mice (n ¼ 4 for each group). The diagram represents an unsupervised two-way hierarchical clustering of the data.
By evaluating the immune response, we observed that the intradermally injected animals showed both innate and secondary immune responses. The presence of TNF, a pro-inflammatory cytokine, triggers the upregulation of ICAM1 and VCAM1 via the nuclear factor kB pathway. 37 As these adhesion molecules do not show upregulation in the microarray in the TNP-treated animals, the increase in the injected animals might be the result of both the injury caused by the invasive administration route and the in situ generated IFN-g. At the same time, high Tlr4, Ccl11 Ccl2 and Ccr2 mRNA levels are signs of innate response to injury. Increased Cd80 and Cd86 indicate the presence of antigen-presenting cells. There was no change in the mRNA levels of surface markers of immune cells such as Cd2, Cd4, Cd28, Cd80 and Cd86, which indicates lack of cellular infiltration (monocytes, macrophages and dendritic cells), in the skin after topical treatment. Contrary to the results seen in intradermally injected animals, Ccl11, Ccl2, and its receptor, Ccr2, were downregulated, indicating the absence of inflammatory processes.
These results underline the importance of the delivery route. By injecting, a series of pro-inflammatory cytokines are triggered, leading to undesired inflammation. Topical administration, on the other hand, is not invasive and does not trigger innate defense. A Th1 immune response was elicited in both TNP and invasive treatment, indicated by the presence of Il12. Il18 (a precursor of Il12) was also upregulated in the TNP-treated animals. No Il2 (induced by Il12) upregulation was observed. Interestingly, in the injected mice, modifications in Il18 and Il2 were not seen, but increased levels of Il15, a cytokine with similar biological role to Il2, were observed. 38 As expected, Jak1/Stat1, triggered by IFN-g, is expressed at higher levels in the injected animals. Smad3 signaling and Tgfb were also upregulated. A downregulation of fibroblast growth factor (Fgf) 18 was observed in the skin of topically treated animals (Table 2b ). In fibrotic disorders, the number of healthy fibroblasts decreases with the progression of the disease and many of them differentiate Topical gene therapy for cutaneous scleroderma I Badea et al into myofibroblasts. These modified cells are characterized by excessive collagen and extracellular matrix production, synthesis of tissue inhibitor metalloproteinase (inhibits collagen degradation), 34 increased reactivity to TGF-b and decreased sensitivity to IFN-g. 33 As the effect of IFN-g on the growth factors is not fully elucidated, further work might be necessary in this area.
In summary, the two routes of administration, either topical treatment or intradermal injection, induced changes in some of the evaluated categories in the skin. mRNA levels of adhesion molecules, Icam1 and Vcam1, were elevated in injected animals, but collagen synthesis was less affected (Col 1a1 and Col 4a1 levels, Po0.1). The TNP-treated animals did not show upregulation of adhesion molecule mRNAs, and collagen synthesis was moderately reduced. The generated IFN-g induced Th1 type cytokines after both topical treatment and injection of animals. After invasive treatment, the increased level of Ccl2 and Ccl11, and surface markers Cd80 and Cd86 would be indicative of cellular infiltration. Generally, growth factors showed little changes.
Biological effect of transgene IFN-c on molecular and cellular markers of scleroderma: real-time PCR measurements of collagen and ICAM1 Transfected keratinocytes in the skin could potentially act as 'mini bioreactors', to produce an immunomodulator such as IFN-g, and participate in immune processes. 34 . It was hypothesized that IFN-g produced by transfected keratinocytes would diffuse through the epidermis into the dermis, where it would reduce collagen synthesis by fibroblasts directly by possibly interfering with the YB-1 pathway, and indirectly by the Jak/Stat1 signaling pathway. Additionally, IFN-g would upregulate surface expression of ICAM1 on keratinocytes. To evaluate these biological effects of the in situ generated IFN-g, we focused our attention on changes in levels of murine procollagen type Ia1 mRNA and ICAM1 mRNA. These markers were determined quantitatively by real-time PCR (Table 3) . The 20-day treatment reduced procollagen type Ia1 mRNA levels in the topically treated and injected animals, and induced a significant decrease in collagen levels compared with untreated animals (Po0.01). Approximately 70% reduction of procollagen mRNA was achieved by both injection and topical treatment. The IFN-g generated by injections of pGTmCMV.IFN-GFP solution was associated with the highest level of transgene expression (1069 pg cm À2 ; Figure 4 ). ICAM1 was upregulated by 50% in both topically treated and injected animals.
Histopathology
Evidence for reduced collagen deposition in the skin was also obtained by evaluating the dermal thickness in histological sections ( Figure 7 ). Tsk1/ þ mice develop hypertrophy of the connective tissue, bone and cartilage. The structure of the skin of Tsk1/ þ mice is different from their homozygous siblings in tensile properties and histology. Normal skin shows difference in the longitudinal and transversal tensile properties, because of the organization of collagen fibers, thus puncture wounds show an elliptical pattern. Tsk1/ þ skin, on the other hand, presents nearly round puncture wounds, an indication of disorganized and densely packed collagen, which is also evidenced by histological staining. 39 Histological examination of skin sections stained with hematoxylin --eosin revealed a thicker dermis of Tsk1/ þ mice compared with normal animals, with excessive deposition of collagen fibers extending into the underlying adipose tissue. 15 In the skin of animals treated topically with TNP-2 formulation (Figure 7a ), or injected with DNA solution (Figure 7b) , the thickness of the dermal layer (indicated by arrows) is reduced compared with untreated animals (Figure 7c ). The homozygous littermates of the Tsk1/ þ animals, without the tight-skin mutation (Figure 7d) , showed similar dermal thickness to the Tsk1/ þ animals treated with TNP-2 and intradermal injection, indicating that in addition to collagen reduction, the clinical manifestation of the disease could also be reduced. McGaha et al. 40 indicated that a twofold decrease in skin thickness after intraperitoneal injection of halofuginone for 60 days was associated with reduced collagen synthesis, evidenced in fibroblast cell culture exposed to halofuginone. Collagen a21 mRNA levels were significantly reduced 8 h after treatment and completely inhibited by 12 h. Additionally, collagen levels were reduced in fibroblast cultures derived from Tsk1/ þ animals.
Here, we have demonstrated that in situ generated IFN-g from injected plasmid DNA can significantly reduce collagen levels in a Tsk/ þ mouse model. Topical application of plasmid DNA coding for IFN-g in cationic TNP formulations also can induce a decrease in collagen synthesis. The absence of IFN-g in the serum might suggest minimal systemic exposure to the protein; hence, side effects previously observed in the clinical trials could be avoided by topical administration of plasmid DNA via the TNP delivery system. The present data suggest that topical application of IFN-gcoding plasmid DNA using cationic gemini delivery vehicles significantly enhances cutaneous IFN-g levels after application to intact skin and appears to be comparable or more efficient than other non-viral delivery systems tested in vivo. 41 --43 Additionally, its effect on collagen synthesis indicates the feasibility of this application to treat cutaneous involvement of scleroderma in humans.
MATERIALS AND METHODS

Topical formulations
The pGTmCMV vector with the murine cytomegalovirus (CMV) promoter designed for gene therapy was used, and the genes coding for IFN-g and GFP were inserted in a bicistronic system. 16 The topical cationic nanoparticles (TNP) were prepared with 1,2-dioleoyl-sn-glycero-phosphatidylethanolamine (DOPE; Avanti Polar Lipids, Alabaster, AL, USA), 25 mg g À1 , purified phosphatidylcholine from soybean lecithin 25 mg g À1 , and the 16-3-16 gemini surfactant 10 mg g À1 formulation, an in-house synthesized amino acid derivative (PDM 27) 10 mg g À1 , propylene glycol 70 mg g À1 and a-tocopherol as an antioxidant. The applied dose was 100 mg plasmid per 100 mg formulation per cm 2 skin area.
Topical treatment
The animal experiments were approved by the University of Saskatchewan Committee on Animal Care and Supply Protocol Review. The animals used for the experiments were 4-to 8-week-old female Tsk/ þ mice (B6.CgFbn1 Tsk þ / þ Pldn pa /J, The Jackson Laboratory, Bar Harbor, ME, USA) and their homozygous, non-diseased pa/pa littermates (Pldn pa þ / þ Pldn pa , The Jackson Laboratory). The animals were anesthetized with isoflurane and close-shaved 1 day before treatment and daily thereafter. The shaved area was cleaned with distilled water and dried using sterile gauze. On the shaved 1 Â 1 cm 2 back area, the 100 mg containing formulation 100 mg pGTmCMV.IFN-GFP plasmid was applied, then covered with parafilm for occlusion and sealed with Op-site. Then the animals were placed in individual restrainers for 2 h to recover and to facilitate absorption of the formulation without animal grooming. The treatment was applied once daily for 5 days per week and lasted for 4 weeks. The animals were reshaved once weekly. Each animal received 500 mg plasmid per week. As a control, the animals were intradermally injected on their backs at four locations with aqueous plasmid solution (2.5 mg plasmid per site) twice weekly, for a total duration of 4 weeks. The total dose was 20 mg of plasmid per week. The control animals were shaved and left untreated. Blood and skin biopsies were harvested 24 h after the last treatment.
Sample processing
Plasma was separated by centrifugation of blood collected from animals by cardiac puncture, and stored at À20 1C. The skin was rinsed with distilled water using sterile gauze and the treated areas were excised. Untreated areas were also clipped and excised for control. The samples were snapfrozen in liquid nitrogen and stored at À80 1C. The skin was homogenized under liquid nitrogen using a biopulverizer (a stainless steel cryogenic device to crush skin samples into a powder, BioSpec Products Inc., Bartlesville, OK, USA) and resuspended in 500 ml protein resuspension buffer (phosphate-buffered saline-containing leupeptin 10 mg ml À1 (SigmaAldrich, Oakville, ON, Canada) and soybean trypsin inhibitor 20 mg ml
À1
(Sigma-Aldrich)). The homogenates were vortexed for 1 min, sonicated for 30 s and kept on ice for 1 min. This cycle was repeated three times. All samples were centrifuged at 16 000 g for 15 min. The supernatants, free of cell debris, were collected and stored at À20 1C.
The total RNA from skin homogenates was isolated using RNeasy Lipid Tissue Mini Kit (Qiagen, Mississauga, Canada) according to the manufacturer's protocol. Approximately 20 mg of skin was used for each animal. To the tissue, 500 ml Qiazol reagent was added, and the samples were further homogenized with a Pro200 rotor-stator homogenizer (Pro Scientific Inc., Oxford, CT, USA). After addition of another 500 ml Qiazol reagent, the homogenates were incubated for 5 min at room temperature to dissociate the nucleoprotein complexes. The RNA was extracted after adding 200 ml chloroform (Sigma-Aldrich) by shaking the samples vigorously for 15 s by hand. After 2 min of incubation, the samples were centrifuged at 12 000 g for 15 min at 4 1C. The mixture separated into a bottom phenol --chloroform layer, an intermediate film and a top aqueous layer containing the total RNA. The clear supernatant (B600 ml) was transferred into a fresh tube, and the RNA precipitated with 600 ml of 70% ethanol (prepared with endonuclease-free purified water, (Gibco by Invitrogen, Burlington, Canada)). The samples were added onto the binding membrane in 6 --700 ml portions and centrifuged at 8000 g at room temperature for 20 s. The flow-through was discarded after each centrifugation. The membrane was washed consecutively with 700 ml RW1 wash buffer, twice with 500 ml RPE wash buffer and was dried by centrifugation at 12 000 g for 1 min. The binding columns were transferred into fresh microfuge tubes. The RNA was eluted twice with 30 ml purified water by centrifugation at 12 000 g at room temperature for 1 min. The total RNA was quantified, and integrity verified using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). The single-and double-stranded DNA were digested from the RNA sample (1 mg total RNA) with DNase I (1 U ml À1 ), and incubated for 15 min at room temperature to complete the reaction. The DNase I was inactivated by addition of 25 mM ethylenediaminetetraacetic acid. Samples were heated for 10 min to 65 1C at which point the RNA samples were ready to be used in reverse transcription before amplification. First-strand cDNA was synthesized using Superscript II for reverse transcription PCR. RNA sample (1 mg), 20 mM Oligo(dT) 12À18 and 10 mM dNTPs were mixed and heated to 65 1C for 5 min, then quickly chilled on ice. The contents of the tube were collected by brief centrifugation. First strand buffer, 0.1 M dithiothreitol and RNase inhibitor (40 U ml À1 ) were added. The contents of the tubes were mixed gently and incubated at 42 1C for 2 min. Superscript II was added and mixed by pipetting up and down. After 50 min incubation at 42 1C, the enzyme was inactivated by heating to 70 1C for 15 min. The cDNA was used for real-time PCR.
Enzyme-linked immunosorbent assay (ELISA) ELISAs were performed using round-bottom 96-well plates (Immulon II, Dynatech Laboratories, Chantilly, VA, USA). The plates were coated with 50 ml per well capture antibody, rat anti-mouse IFN-g (2 mg ml À1 ) in coating buffer (0.05 M NaHCO 3 , pH ¼ 9.6) and incubated for 24 h at 4 1C. The wells were blocked with 1% bovine serum albumin (BSA) (New England Biolabs, Mississauga, Canada) in phosphate-buffered saline at room temperature for 1 h. Recombinant murine IFN-g standard was used in 2000 pg ml
concentration and was consecutively diluted one in four with 1% BSA solution on plates. As a blank control, 1% BSA solution was used. The supernatants from cell cultures, as well as the skin and lymph homogenates and the serum from mice, were diluted one in four on plates. The plates were incubated overnight at 4 1C, biotinylated rat antimouse IFN-g (0.5 ng ml À1 in 1% BSA solution) was added. The plates were incubated for 2 h at room temperature. The streptavidin --alkaline phosphatase conjugate (Invitrogen Life Technologies, Carlsbad, CA, USA) was added in 1:1000 dilution, and incubated for 1 h at room temperature. The 4-nitrophenyl phosphate di(tris) salt 1 mg ml À1 in PNPP buffer (1% diethanolamine, 0.5 mM MgCl 2 , pH¼ 9.8) (Sigma-Aldrich) was used to develop the assay. Optical density of the samples was measured at 405 nm, using a Microplate Reader Benchmark (BioRad, Mississauga, Canada) instrument, and the concentration of IFN-g was calculated from a standardized IFN-g curve. Antibodies and recombinant murine IFN-g were purchased from Pharmingen, Mississauga, Canada.
Microarray and analysis
Total RNA was used for hybridization. GEArray Service (SuperArray Bioscience Corp., Frederick, MD, USA) performed hybridization and chemiluminescent measurements of the individual values. 44 Customdesigned arrays contained 110 genes in five categories:
Mouse Th1/Th2/Th3 indicators: Cd2, Cd28, Cd4, Cd40, Cd69, Cd80, Cd86 antigen, granulocyte --macrophage colony stimulating factor (Gmcsf) 2, cytotoxic T-lymphocyte-associated protein (Ctla) 4, interferon (Ifn) g, IL2, Il4, Il5, Il6, Il7, Il9, Il10, Il12b, IL12 receptor b2 (Il12rb2), Il13, Il15, Il18, Il27, IRF)1, IRF4, toll-like receptor (Tlr) 4, Tlr6, tumor necrosis factor (TNF) and Fas.
Mouse autoimmune disease and inflammatory response genes: fibroblast growth factor (Fgf) 1, Fgf2, Fgf3, Fgf4, Fgf5, Fgf6, Fgf7, Fgf8, Fgf9, Fgf10, Fgf11, Fgf12, Fgf13, Fgf14, Fgf15, Fgf17, Fgf18, Fgf20, Fgf23, Il1a, Il1b, TGFb1, TGFb2 and TGFb3.
Mouse extracellular matrix and adhesion molecules: Cd44, cadherin (Cdh) 1, Cdh2, Cdh3, Cdh4, Cdh5, contactin 1, procollagen type I a1(Col 1a1), Col 3a1, Col 4a1, connective tissue growth factor, extracellular matrix protein (Ecmp) 1, fibronectin (Fn) 1, intercellular adhesion molecule (Icam) 1, integrin (Itg) a2, laminin (Lam) a1, matrix metallopeptidase (Mmp) 3, Mmp7, Mmp10, Mmp13, membrane-inserted Mmp14, matrix Mmp16, Mmp19, interstitial collagenase Mmp1a, platelet/endothelial cell adhesion molecule (Pecam) 1, endothelial cell selectin (Sele), thrombospondin (Thbs) 1, vascular cell adhesion molecule (VCAM) 1, A disintegrinlike and metallopeptidase with thrombospondin (Adamts) type 1 motif 2.
Stat/Smad signaling pathway: Jak1, Jak2, Jak3, suppressor of cytokine signaling (Socs) 1, signal transducer and activator of transcription (Stat) 1, Stat4, Stat6, Smad2, Smad3 and Smad7.
Cell surface markers: C1Q and collagen domain-containing adiponectin (Adipoq), acidic keratin complex (Krt) 1 gene 10, (Krt1-10), Krt1-17, Cd83, Itga2, fibronectin receptor a (Itga5), ItgaX, Itgb2, Itgb3, Itgb5, Itgb7, elastin, small chemokine (C --C motif) ligand (Ccl) 2, Ccl5, Ccl11, Ccl20, Ccl receptor (Ccr)1 and Ccr2.
Housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase), positive and negative controls (PUC18 plasmid DNA, artificial sequences, biotinylated sequences and heat shock proteins) were included on the membranes.
Microarray data were first examined from a strict quality control perspective. Visual inspection of array images was performed to determine any significant artifacts. None were found. The raw quantified data were imported into the R statistical framework and summary statistics including correlation coefficients between arrays, box plots and density plots were performed. No arrays were found to be otherwise skewed or flagged as bad. Subsequently, data were imported into Genespring (Agilent Technologies, Mississauga, Canada) for subsequent filtering, normalization and statistical analysis.
On an individual spot basis, a flag representing the reliability of detection as per Superarrays guidelines and output was used as a first step in filtering. In any combination of experiments used for analysis, only spots flagged as present in at least 50% of samples were used for subsequent analysis. Furthermore, as it is well known that low-intensity measurements are prone to error, 45 only spots above a measured value of 248 in 50% of samples used in an experiment combination were allowed, where 248 represents the average measurement of the median intensities for all arrays. Numbers below 248 were most often flagged as absent by Superarray.
In contrast to microarray experiments dealing with large numbers of genes, the Superarray chips have a significantly smaller number of genes represented, and these genes were chosen based on the prediction that they might be varying. Therefore, normalization on a chip-per-chip basis was not performed. Instead, normalization was performed per gene by dividing gene expression measurements by the median value for that gene across all experiments. All statistical t-tests were performed without any multiple testing corrections, as the small number of tests performed would only yield a very small number (o3) of false positives at the Pp0.05 level.
Real-time PCR
The cDNA was used to run real-time PCR using RT 2 Real-time gene expression kit (SA Biosciences, Frederick, MD, USA) and primer sets for mouse procollagen type Ia1 (NCBI RefSeq Accession #NM 007742) amplifying 122-bp fragments and mouse ICAM-1 (NCBI RefSeq Accession #NM 010493) amplifying 185-bp fragments. Glyceraldehyde-3-phosphate dehydrogenase (NCBI RefSeq Accession #NM 008084), a ubiquitous gene, was used as housekeeping gene (two primer sets amplifying 203 and 128-bp fragments) (all reagents from SuperArray Bioscience Corp.). SYBR green was used to quantify double-stranded DNA. The reactions were carried out under the following conditions: hot start for 15 min at 94 1C, denaturation at 94 1C for 30 s, annealing at 56 1C for 30 s, extension at 72 1C for 30 s in 40 cycles and final extension at 72 1C for 7 min, followed by melting curve between 45 --100 1C in 1 1C increments for 10 s. The quantification (Eq 1) was based on the ratio between the gene of interest detected in the treated and untreated animals, standardized to the housekeeping gene: 46 ratio ¼ 2
À½DCpsampleÀDCpcontrol ð1Þ
where DCp sample is the Cp deviation of untreated---treated of the target gene transcript, and DCp control is the Cp deviation of untreated---treated of the reference gene transcript.
To confirm the size of the product, the fragments were separated by 2% agarose gel electrophoresis at 10 V cm À1 .
Confocal microscopy
Whole-skin biopsies were mounted on glass slides with glass coverslips. Confocal one-photon images were collected from whole-skin biopsies using an argon ion laser source and a Zeiss LSM410 microscope (Carl Zeiss Canada Ltd, Toronto, Canada) with a 40 Â Plan Neo-Fluar oil immersion objective lens with resolution of 0.229 mm. A baseline measurement (autofluorescence) was performed at a 488-nm excitation wavelength and a 630 --680-nm emission band, and the laser intensity adjusted. GFP fluorescence was measured using the same settings with a 510 --560-nm band filter. Four consecutive scans were averaged for image acquisition. The two images were obtained sequentially and merged with LSM410 software.
Statistical analysis
Statistical analyses were performed by analysis of variance (Tukey's test) and Pearson correlation. Significant differences among treatment groups were observed at Po0.05; moderately significant differences among treatment groups were observed at Po0.1.
